The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis

Systematic Reviews

Volumn 4, Issue 1, 2015, Pages

  Meeker, Amanda S ^a   Herink, Megan C ^a   Haxby, Dean G ^a   Hartung, Daniel M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antidepressant; Depression; Meta analysis; Systematic review

Indexed keywords

DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; VENLAFAXINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; SULFIDE;

ARTICLE; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HAMILTON DEPRESSION RATING SCALE; HUMAN; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; DEPRESSIVE DISORDER, MAJOR; NAUSEA; OUTCOME ASSESSMENT; VOMITING;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; NAUSEA; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; SEROTONIN AGENTS; SULFIDES; VOMITING;

EID: 84939186720     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-015-0001-y     Document Type: Article

References (30)

1. Gartlehner G, Hansen R, Morgan L, Thaler K, Lux L, Van Noord M, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 Comparative Effectiveness Review, (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center, Contract No. 290-2007-10056-I.) AHRQ Publication No. 12-EHC012-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. www.effectivehealthcare.ahrq.gov/reports/final.cfm .
2. Gelenberg AJ, Freeman M, Markowirz J, Rosenbaum J, Thase M, Trivedi M, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association; 2010.
3. Guideline NICE. Depression: The treatment and management of depression in adults (NICE clinical guideline 90). London: NICE; 2009. Available at http://www.nice.org.uk/nicemedia/pdf/cg90niceguideline.pdf .
4. FDA. Brintellix (vortioxetine): Highlights of Prescribing Information. Brintellix Label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
5. Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl). 2011;213:265-87.
6. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:589-600.
7. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-60.
8. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-5.
9. Oregon Evidence-Based Practice Center. Drug Effectiveness Review Project: systematic review methods and procedures. Available at http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy-center/derp/documents/upload/DERP_METHODS_WEB_Final_January-2011-2.pdf
10. StataCorp. Stata Statistical Software: Release 13. College Station, Tx: Statacorp LP; 2013.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med. 2009;6:e1000097.
12. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73:953-9.
13. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22:482-91.
14. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;2012(27):215-23.
15. Boulenger, J.-P., Loft, H. & Olsen, C. K. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2013.
16. Takeda Pharmaceuticals Inc, Lundbeck. Brintellix Formulary Dossier. 2013.
17. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16:313-21.
18. Mahableshwarkar A, Jacobsen P, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29:217-26.
19. More than two treatment groups. 2002. (Accessed 05/13/2014, at http://handbook.cochrane.org/chapter_16/16_5_4_how_to_include_multiple_groups_from_one_study.htm .)
20. Application Number: 204447Orig1s000: FDA Medical Review - Vortioxetine. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
21. Center for Drug Evaluation and Research. Application Number: 204447Orig1s000: FDA Clinical Pharmacology and Biopharmaceutics Review(s) - Vortioxetine. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000ClinPharmR.pdf
22. European Medicines Agency. Brintellix European Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002717/human_med_001714.jsp&mid=WC0b01ac058001d124 . Accessed May 20, 2014.
23. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22:1572-8.
24. McDonagh MS, Peterson K, Balshem H, Helfand M. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews. J Clin Epidemiol. 2013;66:1071-81.
25. Spielmans GI, Kirsch I. Drug approval and drug effectiveness. Annu Rev Clin Psychol. 2014;10:741-66.
26. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol FirstView. 2014;1-11.
27. Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high-impact journals. JAMA. 2014;311:1063-5.
28. Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;160:477-83.
29. Earley A, Lau J, Katrin U. Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study. BMJ Open. 2013;3:e001963.
30. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-5.